Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 941.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 191,603 shares of the company's stock after buying an additional 173,211 shares during the period. JPMorgan Chase & Co. owned 0.37% of Janux Therapeutics worth $10,258,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its stake in Janux Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company's stock valued at $114,379,000 after purchasing an additional 288,402 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Janux Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company's stock worth $30,107,000 after buying an additional 38,490 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Janux Therapeutics by 16.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 273,135 shares of the company's stock valued at $14,624,000 after buying an additional 38,944 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Janux Therapeutics by 715.0% in the fourth quarter. Victory Capital Management Inc. now owns 242,409 shares of the company's stock worth $12,979,000 after buying an additional 212,664 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ boosted its position in Janux Therapeutics by 492.2% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 205,167 shares of the company's stock worth $10,771,000 after acquiring an additional 170,520 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on JANX. Scotiabank decreased their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. Lifesci Capital raised Janux Therapeutics to a "strong-buy" rating in a research note on Friday, December 27th. William Blair reissued an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Finally, Wedbush restated an "outperform" rating and set a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $95.25.

Insider Buying and Selling

In related news, Director Ra Capital Management, L.P. purchased 341,742 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were bought at an average cost of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the purchase, the director now directly owns 9,658,988 shares of the company's stock, valued at approximately $295,951,392.32. This trade represents a 3.67 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the transaction, the insider now owns 82,139 shares of the company's stock, valued at approximately $3,473,658.31. The trade was a 3.90 % decrease in their position. The disclosure for this sale can be found here. 29.40% of the stock is currently owned by insiders.

Janux Therapeutics Stock Up 3.5 %

NASDAQ JANX traded up $1.00 during trading on Friday, hitting $29.69. The stock had a trading volume of 367,166 shares, compared to its average volume of 854,854. The company has a market capitalization of $1.75 billion, a PE ratio of -25.38 and a beta of 3.27. The firm has a 50 day moving average price of $30.67 and a 200 day moving average price of $43.60. Janux Therapeutics, Inc. has a twelve month low of $22.52 and a twelve month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.